Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canadian lab extends diagnosis capacity:

This article was originally published in Clinica

Executive Summary

Canada's National Microbiology Laboratory (NML) has received its second shipment of biosafety level 4 viruses. The delivery, from Maryland, US, includes more than a dozen reference virus strains. The NML, which specialises in diagnosis and research on what are billed by Health Canada as "some of the world's most dangerous infectious diseases", is located at the Canadian Science Centre for Human and Animal Health, in Winnipeg. The centre is the first facility in the world to accommodate both human and animal health facilities at the highest level of biocontainment, allowing researchers from both the NML and the National Centre for Foreign Animal Disease to collaborate on research into diseases affecting both humans and animals. The NML received its first shipment of biosafety level 4 viruses in June 2000.

You may also be interested in...

Sanofi CEO Hudson Delivers An Ambitious Turnaround Agenda

CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model. 

Sanofi Has The Fire Power For Deals, CEO Hudson Says

The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.

Corindus Envisions Network Of CorPath Robots For Remote Neurovascular And Coronary Interventions

The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts